5-(3,4-dihydroxybenzylidene)-2-thioxo-dihyropyrimidine-4,6(1H,5H)-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(3,4-dihydroxybenzylidene)-2-thioxo-dihyropyrimidine-4,6(1H,5H)-dione
• 英文别名: 5-(3,4-dihydroxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione；5-(3,4-dihydroxybenzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione；5-[(3,4-dihydroxyphenyl)methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
• 化学式: C₁₁H₈N₂O₄S
• 分子量: 264.262
• InChiKey: DELWWBDBFMAAMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  131
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(3,4-dihydroxybenzylidene)-2-thioxo-dihyropyrimidine-4,6(1H,5H)-dione 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以92.6%的产率得到5-(3,4-dihydroxybenzyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
  参考文献：
  名称：

  발모촉진용 조성물

  摘要：

  本发明涉及一种新的巴比妥酸（Barbiturate）和硫代巴比妥酸（thiobarbiturate）衍生物以及它们用于促进头发生长的组合物，所述的巴比妥酸（Barbiturate）和硫代巴比妥酸（thiobarbiturate）衍生物不仅可以促进动物模型中的毛发生长，还可以通过促进Wnt/β-连环蛋白和毛发生长因子的信号传导调节，抑制细胞凋亡机制，从而促进头发生长，显示出优异的促发效果，因此，本发明的巴比妥酸（Barbiturate）和硫代巴比妥酸（thiobarbiturate）衍生物可用作促进头发生长的组合物。

  公开号：

  KR101732929B1
• 作为产物：
  描述：

  4,6-二羟基-2-巯基嘧啶 、 3,4-二羟基苯甲醛 在 bismuth (III) nitrate pentahydrate 作用下， 以 乙醇 为溶剂， 以87%的产率得到5-(3,4-dihydroxybenzylidene)-2-thioxo-dihyropyrimidine-4,6(1H,5H)-dione
  参考文献：
  名称：

  硫代巴比妥类药物作为潜在的抗真菌剂，可控制由念珠菌和隐球菌引起的人类感染

  摘要：

  住院患者可能患有念珠菌和隐球菌感染，加剧了潜在的健康状况。由于耐药微生物的发展，我们在此报告一些亚芳基-硫代巴比妥酸酯控制五个念珠菌的潜力。和一种具有医学意义的隐球菌。最初，开发了硝酸铋与硫代巴比妥酸和芳族醛催化的Knoevenagel缩合反应。这个新的程序产生七个新和13已知亚芳基-硫代巴比妥衍生物（1 - 20）具有优异的产率（81-95％）中，用20分钟内的反应时间。评估了所有化合物的抗微生物活性白色念珠菌，热带念珠菌，近平滑念珠菌，C.葡萄牙念珠菌，C.都柏林，和新型隐球菌。几种化合物对至少一种微生物菌株具有与市售药物一样的活性（IC 50  <1.95 µg mL -1）。结果表明，某些新化合物可作为治疗人类真菌感染的新抗菌剂的先导。

  DOI：

  10.1007/s00044-017-2126-0

文献信息

• [EN] COMPOUNDS FOR USE IN CANCER THERAPY<br/>[FR] COMPOSÉS POUR UTILISATION DANS LA THÉRAPIE DU CANCER
  申请人：NUHOPE LLC

  公开号：WO2013024447A1

  公开（公告）日：2013-02-21

  Provided are methods and compositions for use in therapy, and in particular for treating cancer, preferably drug-resistant cancer, and/or radiation resistant cancer. The compounds may be used for reducing tumor size in a mammalian subject and for inducing apoptosis in a tumor cell. The methods are effective on tumor cells that are resistant to drugs such as temozolomide, doxorubicin, and geldanamycin, as well as non-resistant tumor cells. Further provided are barbiturate and thiobarbiturates diene compounds for use in treating cancer, and uses, methods and compositions relating to these compounds.

  提供了用于治疗的方法和组合物，特别是用于治疗癌症，最好是药物耐药性癌症和/或放射线耐药性癌症。这些化合物可用于减小哺乳动物主体的肿瘤大小，并诱导肿瘤细胞凋亡。这些方法对于对于药物如替莫唑胺、多柔比星和格兰达霉素耐药的肿瘤细胞以及非耐药的肿瘤细胞都有效。此外，还提供了用于治疗癌症的巴比妥和硫代巴比妥二烯化合物，以及与这些化合物相关的用途、方法和组合物。
• NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR
  申请人：Chung Hae Young

  公开号：US20140023603A1

  公开（公告）日：2014-01-23

  Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

  提供了一种具有美白皮肤、抗氧化和PPAR活性的新化合物及其医疗用途，该化合物具有美白皮肤的活性，可抑制酪氨酸酶，因此适用于用于美白皮肤的药物组合物或化妆品；具有抗氧化活性，因此适用于预防和治疗皮肤老化；具有PPAR活性，特别是PPARα和PPARγ活性，因此适用于用于预防和治疗肥胖、代谢性疾病或心血管疾病的药物组合物或保健食品。
• COMPOUNDS FOR USE IN CANCER THERAPY
  申请人：Connor James R.

  公开号：US20150065531A1

  公开（公告）日：2015-03-05

  Provided are methods and compositions for use in therapy, and in particular for treating cancer, preferably drug-resistant cancer, and/or radiation resistant cancer. The compounds may be used for reducing tumor size in a mammalian subject and for inducing apoptosis in a tumor cell. The methods are effective on tumor cells that are resistant to drugs such as temozolomide, doxorubicin, and geldanamycin, as well as non-resistant tumor cells. Further provided are barbiturate and thiobarbiturates diene compounds for use in treating cancer, and uses, methods and compositions relating to these compounds.

  提供了用于治疗疾病的方法和成分，特别是用于治疗癌症，优选为耐药性癌症和/或放射线耐药性癌症。这些化合物可用于减小哺乳动物主体的肿瘤大小，并诱导肿瘤细胞凋亡。这些方法对于耐药性药物如替莫唑胺、多柔比星和格尔达纳霉素以及非耐药性肿瘤细胞都有效。此外，还提供了用于治疗癌症的巴比妥和硫代巴比妥二烯化合物，以及与这些化合物相关的用途、方法和组合物。
• NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF
  申请人：Pusan National University Industry-University Cooperation Foundation

  公开号：US20160102065A1

  公开（公告）日：2016-04-14

  Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

  提供了一种具有美白、抗氧化和PPAR活性的新化合物及其医疗用途。该化合物具有抑制酪氨酸酶的美白活性，因此可用于美白药物组合物或化妆品产品；具有抗氧化活性，因此可用于预防和治疗皮肤老化；具有PPAR活性，特别是PPARα和PPARγ活性，因此可用于有效预防和治疗肥胖症、代谢疾病或心血管疾病的药物组合物或保健食品。
• Synthesis and structure–activity relationship of thiobarbituric acid derivatives as potent inhibitors of urease
  作者：Khalid Mohammed Khan、Fazal Rahim、Ajmal Khan、Muhammad Shabeer、Shafqat Hussain、Wajid Rehman、Muhammad Taha、Momin Khan、Shahnaz Perveen、M. Iqbal Choudhary

  DOI：10.1016/j.bmc.2014.05.057

  日期：2014.8

  A series of thiobarbituric acid derivatives 1-27 were synthesized and evaluated for their urease inhibitory potential. Exciting results were obtained from the screening of these compounds 1-27. Compounds 5, 7, 8, 11, 16, 17, 22, 23 and 24 showed excellent urease inhibition with IC50 values 18.1 ± 0.52, 16.0 ± 0.45, 16.0 ± 0.22, 14.3 ± 0.27, 6.7 ± 0.27, 10.6 ± 0.17, 19.2 ± 0.29, 18.2 ± 0.76 and 1.61 ± 0.18 μM, respectively, much better than the standard urease inhibitor thiourea (IC₅₀=21 ± 0.11 μM). Compound 3, 4, 10, and 26 exhibited comparable activities to the standard with IC₅₀ values 21.4 ± 1.04 and 21.5 ± 0.61 μM, 22.8 ± 0.32, 25.2 ± 0.63, respectively. However the remaining compounds also showed prominent inhibitory potential The structure-activity relationship was established for these compounds. This study identified a novel class of urease inhibitors. The structures of all compounds were confirmed through spectroscopic techniques such as EI-MS and (1)H NMR.